Harvard Apparatus Regenerative Technology Q3 2026 diluted loss per share more than doubles to $0.58
HRGN•Harvard Apparatus Regenerative Technology reported third-quarter adjusted loss per share of $0.06, up 50% year over year, while revenue rose 8% to $22.2 million. It cut FY26 adjusted EBITDA growth guidance to a range of a 1% decline to 4% growth but kept revenue growth guidance at 3%-5%.
1. Quarterly results and outlook
Third-quarter 2026 revenue rose 8% year over year to $22.2 million, driven by strong sales to CROs and customers in China. The company said Project Viking remains on track for completion by the end of the first quarter of 2027. FY26 adjusted EBITDA growth guidance was reduced from 6%-10% growth to a range of a 1% decline to 4% growth; revenue growth guidance remained 3%-5%, and fourth-quarter revenue is projected at $23.7 million-$25.5 million.
